Consistent with reports for other Hsp90 inhibitors [24, 27, 28], ganetespib treatment was strongly cytotoxic to HER2-overexpressing cell lines in vitro and induced robust tumor regression in BT-474 xenografts. The gene discussed is ERBB2; the disease is neoplasm.